Grace Therapeutics (GRCE) EBITDA Margin (2020 - 2021)
Grace Therapeutics (GRCE) posted EBITDA Margin of 2000.0% for Q1 2021, up 17.52% sequentially from 2424.69% in Q4 2020.
Grace Therapeutics (GRCE) EBITDA Margin (2020 - 2021) Analysis & Trends
Grace Therapeutics has reported EBITDA Margin for 2 years, with the latest figure at 2000.0% in Q1 2021.
- Quarterly EBITDA Margin changed N/A year-over-year to 2000.0% in Q1 2021, while the trailing twelve-month figure through Mar 2022 was 7953.57% (changed N/A YoY) and the FY2021 annual result came in at 8377.04%, changed N/A from the prior year.
- EBITDA Margin grew to 2000.0% in Q1 2021 per GRCE's latest filing, from 2424.69% in the prior quarter.
- Over five years, EBITDA Margin peaked at 2000.0% in Q1 2021 and troughed at 2424.69% in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | -2,000.00% |
| Dec 31, 2020 | -2,424.69% |